



cagp

CANADIAN ACADEMY OF
GERIATRIC PSYCHIATRY

acpg

L'ACADÉMIE CANADIENNE
DES PSYCHIATRIE GÉRIATRIQUE

Advanced Interactive Case-based Workshop on Pharmacology on Depression and Dementia

Benoit H. Mulsant, MD, MS, DFAPA
Professor and Chair
Department of Psychiatry
University of Toronto
Senior Scientist
Centre for Addiction and Mental Health



Faculty/Presenter Disclosure

- **Faculty: Benoit H. Mulsant**
- **Relationships with commercial interests (past 5 years):**

Grants/Research Support: **Current: Brain Canada, Canadian Institute of Health Research, National Institute of Health, Several Foundations**

Bristol-Myers Squibb, Eli Lilly, and Pfizer have provided medications (or matched placebo pills) for NIMH-funded clinical trials

Speakers Bureau/Honoraria: None

Consulting Fees: None

Other: **Current: Center for Addiction and Mental Health, University of Toronto, University of Pittsburgh, Roche (travel support in 2011)**

Disclosure of Commercial Support

This program has received no financial or in-kind support from any commercial organizations.

Potential for conflicts of interest:

The use of all available antidepressants, antipsychotics, and several other psychotropic medications will be discussed during this program.

Mitigating Potential Bias

Generic names will be used.

Generic forms are available for most medications that will be mentioned.

Key Learning Objectives

At the conclusion of this session, the participants should be able to:

1. Assess the evidence supporting the efficacy of antidepressant medications in the treatment of late-life depression.
2. Assess the risks of antidepressant medications used in the treatment of late-life depression.
3. Discuss strategies to address treatment-resistant late-life depression (i.e., depression that does not respond to an adequate antidepressant trial).